Werth Ventures

DeepLook Medical develops medical imaging software that uses shape-recognition to extract radiomic features from mammography images, revealing tissue morphology not visible to the unaided eye, and aims to improve early breast cancer detection, particularly in dense breast tissue, by identifying subtle data within radiological images and presenting features beyond human vision to help clinicians and reduce unnecessary procedures by lowering false positives.

Cingulate Therapeutics, LLC is a biopharmaceutical company focused on developing innovative treatments for central nervous system and neurobiological disorders, particularly Attention Deficit and Hyperactivity Disorder (ADHD). Established in 2012 and headquartered in Kansas City, Kansas, with an additional office in Morristown, New Jersey, Cingulate is advancing two first-line stimulant medications, CTx-1301 and CTx-1302, designed for comprehensive patient use across all age groups. Utilizing a unique delivery technology, these medications aim to provide rapid onset of action, extended duration of effect, and favorable tolerability in a once-daily oral formulation. The company has partnered with Catalent Pharma Solutions to leverage their OptiDose technology, enhancing manufacturing efficiency and drug delivery. Cingulate's approach addresses significant gaps in the current ADHD treatment landscape, particularly the need for full-day therapeutic efficacy, and targets a substantial market opportunity projected to be worth $2-$3 billion in the combination-dose segment and $9 billion overall.

Cingulate Therapeutics, LLC is a biopharmaceutical company focused on developing innovative treatments for central nervous system and neurobiological disorders, particularly Attention Deficit and Hyperactivity Disorder (ADHD). Established in 2012 and headquartered in Kansas City, Kansas, with an additional office in Morristown, New Jersey, Cingulate is advancing two first-line stimulant medications, CTx-1301 and CTx-1302, designed for comprehensive patient use across all age groups. Utilizing a unique delivery technology, these medications aim to provide rapid onset of action, extended duration of effect, and favorable tolerability in a once-daily oral formulation. The company has partnered with Catalent Pharma Solutions to leverage their OptiDose technology, enhancing manufacturing efficiency and drug delivery. Cingulate's approach addresses significant gaps in the current ADHD treatment landscape, particularly the need for full-day therapeutic efficacy, and targets a substantial market opportunity projected to be worth $2-$3 billion in the combination-dose segment and $9 billion overall.

Cingulate Therapeutics, LLC is a biopharmaceutical company focused on developing innovative treatments for central nervous system and neurobiological disorders, particularly Attention Deficit and Hyperactivity Disorder (ADHD). Established in 2012 and headquartered in Kansas City, Kansas, with an additional office in Morristown, New Jersey, Cingulate is advancing two first-line stimulant medications, CTx-1301 and CTx-1302, designed for comprehensive patient use across all age groups. Utilizing a unique delivery technology, these medications aim to provide rapid onset of action, extended duration of effect, and favorable tolerability in a once-daily oral formulation. The company has partnered with Catalent Pharma Solutions to leverage their OptiDose technology, enhancing manufacturing efficiency and drug delivery. Cingulate's approach addresses significant gaps in the current ADHD treatment landscape, particularly the need for full-day therapeutic efficacy, and targets a substantial market opportunity projected to be worth $2-$3 billion in the combination-dose segment and $9 billion overall.

Founded in 2013, Torigen Pharmaceuticals specializes in developing innovative cancer care solutions for pets. Based in Farmington, Connecticut, the company focuses on advancing scientific research to bring novel approaches to companion animal cancers.

Bastion Health is a digital clinic specializing in men's healthcare. It offers at-home diagnostics and virtual specialty care for prostate, reproductive, hormonal balance issues, and early cancer detection. The company aims to enhance accessibility, affordability, and comprehensiveness of men's health services.

VeraDermics is a dermatology company specializing in novel drug delivery mechanisms. It offers a dissolvable microneedle patch for treating skin conditions like warts, administering immunotherapy painlessly by stimulating the body's immune system.

MedRhythms Inc. is a neuro-rehabilitation company that specializes in neurologic music therapy, employing sensors, music, and artificial intelligence to create evidence-based interventions aimed at enhancing walking and overall functional outcomes. Founded in 2015 and headquartered in Portland, Maine, the company addresses the needs of individuals affected by neurological conditions such as traumatic brain injury, stroke, Parkinson’s disease, and Huntington’s disease. By merging music with neuroscience and technology, MedRhythms develops programs that focus on sensorimotor, speech, language, and cognitive rehabilitation goals, allowing patients to leverage music as a therapeutic tool to stimulate brain function and improve their quality of life.

Bastion Health is a digital clinic specializing in men's healthcare. It offers at-home diagnostics and virtual specialty care for prostate, reproductive, hormonal balance issues, and early cancer detection. The company aims to enhance accessibility, affordability, and comprehensiveness of men's health services.

Cingulate Therapeutics, LLC is a biopharmaceutical company focused on developing innovative treatments for central nervous system and neurobiological disorders, particularly Attention Deficit and Hyperactivity Disorder (ADHD). Established in 2012 and headquartered in Kansas City, Kansas, with an additional office in Morristown, New Jersey, Cingulate is advancing two first-line stimulant medications, CTx-1301 and CTx-1302, designed for comprehensive patient use across all age groups. Utilizing a unique delivery technology, these medications aim to provide rapid onset of action, extended duration of effect, and favorable tolerability in a once-daily oral formulation. The company has partnered with Catalent Pharma Solutions to leverage their OptiDose technology, enhancing manufacturing efficiency and drug delivery. Cingulate's approach addresses significant gaps in the current ADHD treatment landscape, particularly the need for full-day therapeutic efficacy, and targets a substantial market opportunity projected to be worth $2-$3 billion in the combination-dose segment and $9 billion overall.

Likarda is a biotechnology company focused on cell therapies and enabling technologies that improve delivery and function. Its Core-Shell Spherification platform encapsulates therapeutic cells in hydrogel microcapsules using biocompatible materials such as hyaluronic acid, PEG and PVA, enabling customizable formulations tailored to each therapy. The platform supports two delivery approaches: injectable, slow-release formulations that localize cells for enhanced efficacy, and immunoprotective coatings that protect cells during injection or transplantation for longer-term treatment. In addition to cell therapies, the hydrogel coating method can formulate and deliver peptides, antibodies and exosomes while preserving their activity at the target site. Likarda aims to advance therapies for diabetes and osteoarthritis, including islet-like cell delivery for diabetes and encapsulated stem cells for joint degeneration, through preclinical work in animal models.